Autologous (qualifier value)

Aspen Neuroscience Secures $115 Million Series C to Advance Parkinson’s Cell Therapy; IPO Considered for 2026

3 weeks ago talkbio0Tagged Aspen, Bach Flower Essence, Autologous (qualifier value), Cell Therapy, Clinical Trials, Induced Pluripotent Stem Cells, IPO, manufacturing scale-up, Neuroscience discipline, Parkinson 's disease, plans, Regenerative Medicine, Series C financing

Aspen Neuroscience; Series C financing; Parkinson’s disease; cell therapy; ANPD001; autologous iPSC; clinical trials; manufacturing scale-up; IPO plans; regenerative medicine

Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review

11 months ago talkbio0Tagged Astellas, Autologous (qualifier value), Biotechnology, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Lymphoma, Pipeline Review

Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology

FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks

1 year ago talkbio0Tagged Autologous (qualifier value), Automobiles, BCMA, BCMA-directed, boxed, CAR-T therapy, Cautionary Warning, CD19-directed, Neoplasm Metastasis, T-cell immunotherapies, T-Lymphocyte, United States Food and Drug Administration

CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.